Apollo Micro Systems' Strong Earnings Mask Underlying Financial Concerns Apollo Micro Systems Limited (NSE:APOLLO) reported robust earnings, which initially drove its stock price higher. However, analysts caution that the company’s financial health may not be as strong as the profit figures suggest. A closer examination of its financial metrics reveals significant challenges, including negative free cash flow, share dilution, and a high accrual ratio that could signal future profitability risks. The company’s accrual ratio for the fiscal year ending March 2026 stands at 0.36, indicating that a substantial portion of its reported profits are not supported by actual cash flow. This ratio is calculated by subtracting free cash flow from profit and dividing the result by average operating assets. A negative accrual ratio would suggest strong cash flow relative to profits, but a positive ratio, as in this case, raises concerns. Apollo Micro Systems did not generate any free cash flow during the period, and its cash flow was negative in the previous year, with an outflow of ₹3.6 billion despite reporting profits of ₹1.13 billion. This negative free cash flow has raised questions among shareholders about the company’s financial sustainability. The firm’s decision to issue new shares has further diluted existing shareholders’ equity, reducing their share of future earnings. Over the past year, the number of outstanding shares increased by 23%, which means that while net income has grown significantly, earnings per share (EPS) have not kept pace. For example, the company’s profit rose by 100% over the last year, but EPS only increased by 71%. This discrepancy highlights the impact of dilution on shareholder returns.#apollo_micro_systems #earnings_per_share #free_cash_flow #share_dilution #accrual_ratio
UnitedHealth Group's Share Price Plummets 46%: Is It Undervalued? UnitedHealth Group (UNH) has experienced a significant decline in its stock price, with a 46.3% drop over the past year. The stock recently closed at $269.54, reflecting a 5.6% decline in the last week, 7.1% over 30 days, and a 19.9% year-to-date drop. Investors are now questioning whether the company’s valuation has been overly adjusted or if the market has priced in too much pessimism. Analysts and valuation tools suggest the stock may be undervalued. A Discounted Cash Flow (DCF) analysis estimates the company’s intrinsic value at $816.71 per share, implying the current price is approximately 67% below this figure. This projection is based on UnitedHealth Group’s projected free cash flow of $27.8 billion in 2030, with estimates extending through 2035. The DCF model highlights a potential gap between the stock’s current price and its long-term cash flow potential. The company’s price-to-earnings (P/E) ratio of 20.29x also places it below industry and peer averages. The Healthcare sector’s average P/E is 21.22x, while the peer group average is 18.82x. A proprietary “Fair Ratio” calculation by Simply Wall St suggests a P/E of 37.06x, further indicating the stock may be undervalued relative to its growth prospects and risk profile. Investors are divided on the company’s future outlook, with differing narratives shaping valuation expectations. Some argue the stock could approach a Fair Value of $625 per share, while others suggest a lower range near $284. This divergence underscores how market perceptions and assumptions about revenue, earnings, and margins can lead to conflicting conclusions.#healthcare_sector #unitedhealth_group #discounted_cash_flow #simply_wall_st #free_cash_flow
